Treace to Report Third Quarter 2022 Financial Results on November 8, 2022

Rhea-AI Summary

Treace Medical Concepts (NasdaqGS: TMCI) announced it will release its third quarter 2022 financial results on November 8, 2022, post-market. The company focuses on enhancing surgical treatments for bunions, affecting around 65 million Americans. They have developed the patented Lapiplasty® 3D Bunion Correction™ system and recently introduced the Adductoplasty™ Midfoot Correction System. A conference call will follow the earnings release at 4:30 PM ET, where management will discuss the results.

Positive

• Innovative Lapiplasty® 3D Bunion Correction™ and Adductoplasty™ Midfoot Correction System address major market needs.
• Approximately 1.1 million annual surgical candidates in the U.S. present a significant market opportunity.

Negative

• None.

PONTE VEDRA, Fla., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that it will release financial results for the third quarter of 2022 after the close of trading on Tuesday, November 8, 2022. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.

Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.treace.com/.

About Treace Medical Concepts

Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction™ system – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace recently expanded its offering with the Adductoplasty™ Midfoot Correction System, designed for reproducible surgical correction of the midfoot to provide further support to hallux valgus patients. For more information, please visit www.treace.com.

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.com
(904) 373-5940

Investors:
Gilmartin Group
Lynn Lewis or Vivian Cervantes
IR@treace.com

FAQ

When will Treace Medical Concepts release its third quarter 2022 financial results?

Treace Medical Concepts will release its third quarter 2022 financial results on November 8, 2022, after the market close.

What is the focus of Treace Medical Concepts?

Treace Medical Concepts focuses on the surgical treatment of hallux valgus, commonly known as bunions.

What systems has Treace Medical Concepts developed for bunion treatment?

Treace Medical Concepts developed the Lapiplasty® 3D Bunion Correction™ system and the Adductoplasty™ Midfoot Correction System.

What time is the conference call to discuss financial results?

The conference call to discuss financial results will begin at 4:30 PM ET on November 8, 2022.

How many Americans are affected by bunions according to Treace Medical Concepts?

Treace Medical Concepts estimates that approximately 65 million Americans are affected by bunions.